Combination of several treatment regimens such as chemotherapy, radiotherapy, and surgery was always more beneficial for cancer patients than monotherapy. Advances in combination chemotherapy in the 1970s brought improvement of life quality and prolonged patient survival. New types of radiotherapy and progress in noninvasive surgery in the mid-1990s were other milestones in cancer treatment. With human genome sequencing and rapid development of individual medicine approaches, new technologies are needed for successful treatment of cancer and many other pathological conditions. The road map for cancer treatment for the first two decades of twenty-first century is likely to focus on simultaneous inhibition of several cancer-specific molecular markers and/or several altered pathways or on conventional chemotherapy in combination with prevention of synthesis of tumor-specific genes/proteins. The new drug engineering strategies will be based on achievements of genomics and proteomics, production of monoclonal antibodies, nanotechnology, and bioinformatics.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abdellaouri, K., Boustta, M., Vert, M., Marjani, H., and Manfait, M. 1998. Metabolic-derived artificial polymers designed for drug targeting, cell penetration and bioresorption. Eur. J. Pharm. Sci. 6:61–73.
Ahmad, K. A., Wang, G., Slaton, J., Unger, G., and Ahmed, K. 2005. Targeting CK2 for cancer therapy. Anticancer Drugs 16:1037–1043.
Andersson L., Davies, J., Duncan, R., Ferruti, P., Ford, J., Kneller, S., Mendichi, R., Pasut, G., Schiavon, O., Summerford, C., Tirk, A., Veronese, F. M., Vincenzi, V., and Wu, G. 2005. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules 6:914–926.
Arpicco, S., Dosio, F., Bolognesi, A., Lubelli, C., Brusa, P., Stells, B., Ceruti, M., and Cattel, L. 2002. Novel poly(ethylene glycol) derivatives for preparation of ribosome-inactivating protein conjugates. Bioconjug. Chem. 13:757–765.
Bae, Y., Jang, W. D., Nishiyama, N., Fukushima, S., and Kataoka, K. 2005. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol. Biosyst. 1:242–250.
Bickenbach, K., Wilcox, R., Veerapong, J., Kindler, H. L., Posner, M. C., Noffsinger, A., and Roggin, K. K. 2007. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J. Gastrointest. Surg. 11:758–766.
Brekke, O. H. and Sandlie, I. 2003. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2:52–62.
Broadwell, R. D., Baker-Cairns, B. J., Frieden, P. M., Oliver, C., and Villegas, J. C. 1996. Transcytosis of protein through the mammalian cerebral epithelium and endothelium III. Receptormediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. 142:47–65.
Cammas, S., Béar M.-M., Moine, L., Escalup, R., Ponchel, G., Kataoka, K., and Guérin, P. 1999. Polymers of malic acid and 3-alkylmalic acid as synthetic PHAs in the design of biocompatible hydrolysable devices. Int. J. Biol. Macromol. 25:273–282.
Carter, P. J. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6:343–357.
Chatila, K., Ren, G., Xia, Y., Huebener, P., Bujak, M., and Frangogiannis, N. G. 2007. The role of the thrombospondins in healing myocardial infarcts. Cardiovasc. Hematol. Agents Med. Chem. 5:21–27.
Cho, Y. W., Kim, J. D., and Park, K. 2003. Polycation gene delivery systems: escape from endosomes to cytosol. J. Pharm. Pharmacol. 55:721–734.
Chytil, P., Etrych, T., Konak, C., Sirova, M., Mrkvan, T., Rihova, B., and Ulbrich, K. 2006. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification. J. Control. Release 115:26–36.
Coloma, M. J., Lee, H. J., Kurihara, A., Landaw, E. M., Boado, R.J., Morrison, S. L., and Pardridge, W. M. 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17:266–274.
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., and Penichet, M. L. 2006a. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121:144–158.
Daniels, T. R., Delgado, T., Helguera, G., and Penichet, M. L. 2006b. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121:159–176.
Deres, S., Gdalevsky, G. Y., Gilboa, I., Voorspoels, J., Remon, J. P., and Kost, J. 2004. Bioadhesive grafted starch copolymers as platform for peroral drug delivery: a study of theophylline release. J. Control. Release 94:391–399.
Duncan, R. 1992. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3:175–210.
Duncan, R., Seymour, L. C. W., Scarlett, L., Lloyd, J. B., Rejmanová, P., and Kopecek, J. 1986. Fate of N-(2-hydroxypropyl) methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 880:62–71.
Duncan, R., Vicent, M. J., Greco, F., and Nicholson, R. I. 2005. Polymer-drug conjugates: towards a novel approach for the treatment of endocrine-related cancer. Endocr. Relat. Cancer 12:S189–S199.
Ehrlich, P. 1906. Studies in Immunity, New York: Plenum Press.
Etrych, T., Jelinkova, M., Rihova, B., and Ulrich, K. 2001. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release 73:89–102.
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., Armand, J. P., Scigalla, P., and Raymond, E. 2006. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24:25–35.
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., and Langer, R. 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 103:6315–6320.
Fleming, A. B., Haverstick, K., and Saltzman, W. M. 2004. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-Camptothecin conjugates to the rat brain. Bioconjug. Chem. 15:1364–1375.
Fujita, M., Khazenzon, N. M., Bose, S., Sekiguchi, K., Sasaki, T., Carter, W. G., Ljubimov, A. V., Black, K. L., and Ljubimova, J. Y. 2005. Overexpression of β1 chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. Breast Cancer Res. 7:411–421.
Fujita, M., Khazenzon, N. M., Ljubimov, A. V., Lee, B.-S., Virtanen, I., Holler, E., Black, K. L., Ljubimova, J. Y. 2006. Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis 9:183–191.
Fujita, M., Lee, B.-S., Khazenzon, M. N., Penichet, M. L., Wawrowsky, K. A., Patil, R., Ding, H., Holler, E., Black, K. L., and Ljubimova, J. L. 2007. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(β-L-malic acid). J. Control. Release 122:356–363.
Fujiwara, H., Gu, J., and Sekiguchi, K. 2004. Rac regulates integrin-mediated endothelial cell adhesion and migration on laminin-8. Exp. Cell Res. 292:67–77.
Gaur, U., Sahoo, S. K., De, T. K., Ghosh, P. C., Maitra, A., and Ghosh, P. K. 2000. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int. J. Pharm. 202:1–10.
Golenser, J., Frankenburg, S., Ehrenfreund, T., and Domb, A. J. 1999. Efficacious treatment of experimental Leishmaniasis with amphotericin t-arabinogalactan water-soluble derivatives. Antimicrob. Agents Chemother. 43:2209–2214.
Grantab, R., Sivananthan, S., and Tannock, I. F. 2006. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor. Cancer Res. 66:1033–1039.
Greenwald, R. B., Choe, Y. H., McGuire, J., and Conover, C. D. 2003. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55:217–250.
Gupta, B. and Torchilin, V. P. 2007. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother. 56:1215–1223.
Gupta, N. and Yucel, Y. H. 2007. Glaucoma as a neurodegenerative disease. Curr. Opin. Ophthalmol. 18:110–114.
Haider, M., Megeed, Z., and Ghandehari, H. 2004. Genetically engineered polymers: status and prospects for controlled release. J. Contol. Release 95:1–26.
Hallmann, R., Horn, N., Selg, M., Wendler, O., Pausch, F., and Sorokin, L.M. 2005. Expression and function of laminins in the embryonic and mature vasculature. Physiol. Rev. 85:979–1000.
Heaney, N. B. and Holyoake, T. L. 2007. Therapeutic targets in chronic myeloid leukaemia. Hematol. Oncol. 25:66–75.
Iakoubov, L. Z. and Torchilin, V. P. 1997. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol. Res. 9:439–446.
Jabbour, E., Cortes, J., and Kantarjian, H. 2007. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin. Investig. Drugs 16:679–687.
Jatzkewitz, H. 1955. Peptamin (glycyl-L-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (Mescaline). Z. Naturforsch. 10b:27–31.
Jefferies, W. A., Brandon, M. R., Williams, A. F., and Hunt, V. 1985. Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology 54:333–341.
Jensen, K., D., Kopeckova, P., and Kopecek, J. 2002. Antisense oligonucleotides delivered to the lysosome escape and actively inhibit hepatitis B virus. Bioconjug. Chem. 13:975–984.
Kabanov, A. V., Batrakova, E. V., and Alakhov, V. Y. 2002. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 13:759–779.
Kantarjian, H. M., Cortes, J., Guilhot, F., Hochhaus, A., Baccarani, M., and Lokey, L. 2007. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer 109:1365–1375.
Khandare, J. J. and Minko, T. 2006. Antibodies and peptides in cancer therapy. Crit. Rev. Ther. Drug Carrier Syst. 23:401–436.
Khazenzon, N. M., Ljubimov, A. V., Lakhter, A. J., Fujita, M., Fujiwara, H., Sekiguchi, K., Sorokin, L. M., Petajaniemi, N., Virtanen, I., Black, K. L., and Ljubimova, J. Y. 2003. Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol. Cancer Ther. 2:985–994.
Kishore, B. K., Lambricht, P., Laurent, G., Maldague, P., Wagner, R., and Tulkens, P. M. 1990. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids. J. Pharmacol. Exp. Ther. 255:875–885.
Kishore, B. K., Maldague, P., Tulkens, P. M., and Courtoy, P. J. 1996. Pol-D-glutamic acid induces an acute lysosomal thesaurismosis of proximal tubules and a marked proliferation of intrstitium in rat kidney. Lab. Invest. 74:1013–1023.
Konstantinopoulos, P. A., Vandoros, G. P., and Papavassiliou, A. G. 2006. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother. Pharmacol. 58:711–715.
Kopecek, J. and Baziliva, H. 1973. Poly[n-(2-hydroxypropyl) methacrylamide]. 1. Radical polymerization and copolymerization. Eur. Polym. J. 9:7–14.
Kopecek, J., Reijmanová, P, Strohalm, J., Ulbrich, K., Rihová, B., Chytrý, V., Lloyd, J. B., and Duncan, R. 1991. Synthetic polymeric drugs. U.S. Patent. 5, 037, 883.
Kopecek, J., Kopecková, P., Minko, T., and Lu, Z.-R. 2000. HPMA Copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50:61–81.
Kopecek, J., Kopeckova, P., Minko, T., Lu, Z.-R., and Peterson, C. M. 2001. Water soluble polymers in tumor targeted delivery. J. Control. Release 74:147–158.
Korherr, C., Roth, M., and Holler, E. 1995. Poly(β-L-malate) hydrolase from plasmodia of Physarum polycephalum. Can. J. Microbiol. 41(Suppl. 1):192–199.
Kramerov, A. A., Saghizadeh, M., Pan, H., Kabosova, A., Montenarh, M., Ahmed, K., Penn, J. S., Chan, C. K., Hinton, D. R., Grant, M. B., and Ljubimov, A. V. 2006. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am. J. Pathol. 168:1722–1736.
Kumar, D. M., Perez, E., Cai, Z. Y., Aoun, P., Brun-Zinkernagel, A. M., Covey, D. F., Simpkins, J. W., and Agarwal, N. 2005. Role of nonfeminizingestrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity. Free Radic. Biol. Med. 38:1152–1163.
Kunath, K., Kopceckova, P., Minko, T., and Kopecek, J. 2000. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. Eur. J. Pharm. Biopharm. 49:11–15.
Leamon, C. P. and Reddy, J. A. 2004. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. 56:1127–1141.
Leary, S. P., Liu, C.Y., and Apuzzo, M. L. J. 2006. Toward the emergence of nanoneurosurgery: Part III–nanomedicine: targeted nanotherapy, nanosurgery, and progress toward the realization of nanoneurosurgery. Neurosurgery 58:1009–1026.
Lee, B.-S. and Holler, E. 1999. Effects of culture conditions on L-poly(L-malate) production by Physarum polycephalum. Appl. Microbiol. Biotechnol. 51:647–652.
Lee, B.-S., Vert, M., and Holler, E. 2002. Water-soluble aliphatic polyesters: poly(malic acid) s. In Biopolymers. Vol. 3a, eds. V. Doi, and A. Steinbuechel, pp. 75–103. New York:Wiley-VCH.
Lee, B.-S., Fujita, M., Khazenzon, N. M., Wawrowsky, K. A., Wachsmann-Hogiu, S., Farkas, D. L., Black, K. L., Ljubimova, J. Y., and Holler, E. 2006. Polycefin, a new prototype of a multifunctional nanoconjugate based on poly( -L-malic acid) for drug delivery. Bioconjug. Chem. 17:317–326.
Li, C. 2002. Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. 54:695–713.
Ljubimov, A. V., Caballero, S., Aoki, A. M., Pinna, L. A., Grant, M. B., and Castellon, R. 2004. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 45:4583–4591.
Ljubimova, J. Y., Lakhter, A. J., Loksh, A., Yong, W. H., Riedinger, M. S., Miner, J. H., Sorokin, L. M., Ljubimov, A. V., and Black, K. L. 2001. Overexpression of L4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res. 61:5601–5610.
Ljubimova, J. Y., Fugita, M., Khazenzon, N. M., Das, A., Pikul, B. B., Newman, D., Sekiguchi, K., Sorokin, L. M., Sasaki, T., and Black, K. L. 2004. Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer 101:604–612.
Ljubimova, J. Y., Fujita, M., Khazenzon, N. M., Lee, B.-S., Wachsmann-Hogiu, S., Farkas, D. L., Black, K. L., and Holler, E. 2007. Nanoconjugate based on polymalic acid for tumor targeting. Chem. Biol. Interact. In press.
Luo, Y. and Prestwich, G. D. 2002. Cancer-targeted polymeric drugs. Curr. Cancer Drug Targets 2:209–226.
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65:271–284.
Maruyama, K., Takahashi, N., Toshiaki, T., Nagaike, K., and Iwatsuru, M. 1997. Immunoliposomes bearing polyethyleneglycol-coupled Fab’ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 413:177–180.
Mastrobattista, E., Koning, G. A., van Bloois, L., Filipe, A. C., Jiskoot, W., and Storm, G. 2002. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J. Biol. Chem. 277:27135–27143.
Mathé, G., Lo, T. B., and Bernard, J. 1958. Effect sur la leucémie L1210 de la souris d’une combinaison par diazotation d’améthoptérine et de γ-globulines de hamsters porteurs de cette leucémie par hétérogreffe. C. R. Hebd. Seances Acad. Sci. 246:1626–1628.
Maurer, P. H., Gerulat, B. F., and Pinchuck, P. 1964. Antigenicity of polypeptides (pol-M-amino acids). XI. Quantitative relationships among polymers and rabbit antisera. J. Biol. Chem. 239:922–929.
McNamara II, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., and Giangrande, P. H. 2006. Cell type-specific delivery of siRNA aptamer-siRNA chimeras. Nat. Biotechnol. 24:1005–1015.
Merdan, T., Kopecˇek, J., and Kissel, T. 2002. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54:715–758.
Moghimi, S. M., Hunter, A. C., and Murray, J. C. 2005. Nanomedicine: current status and future prospects. FASEB J. 19:311–330.
Montemurro, F., Valabrega, G., and Aglietta, M. 2007. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin. Biol. Ther. 7:257–268.
Murphy, P. D. and Sage, H. J. 1970. Variation in the size of antibody sites for the poly-L-aspartate hapten during the immune response. J. Immunol. 105:460–470.
Murthy, N., Robichaud, J. R., Tirrell, D. A., Stayton, P. S., and Hoffman, A. S. 1999. The design and synthesis of polymers for eukaryotic membrane disruption. J. Control. Release 61:137–143.
Muzykantov, V. R. and Torchilin, V. P, eds. 2003. Biomedical Aspects of Drug Targeting. New York: Springer.
Nakamura, K., Sata, M., Iwata, H., Sakai, Y., Hirata, Y., Kugiyama, K., and Nagai, R. 2007. A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin. Sci. (Lond.) 112:607–616.
Nori, A. and Kopecek, J. 2005. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev. 57:609–636.
Omelyanenko, V., Kopeckova, P., Prakash, R. K., Ebert, C. D., and Kopecek, J. 1999. Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes. Pharm. Res. 16:1010–1019.
Otsuka, H., Nagasaki, Y., and Kataoka, K. 2003. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 55:403–419.
Ouchi, T., Fujino, A., Tanaka, K., and Banba, T. 1990. Synthesis and antitumor activity of conjugates of poly(α-malic acid) and 5-fluoroacils bound via ester, amide or carbamoyl bonds. J. Control. Release 12:143–153.
Pagano, M. A., Cesaro, L., Meggio, F., and Pinna, L. A. 2006. Protein kinase CK2: a newcomer in the ‘druggable kinome’. Biochem. Soc. Trans. 34(Pt 6):1303–1306.
Panarin, E. F. and Ushakov, S. N. 1968. Synthesis of polymer salts and amidopenicillines. Khim. Pharm. Zhur. 2:28–31.
Papisov, M. I. 1998. Theoretical considerations of RES-avoiding liposomes: molecular mechanics and chemistry of liposome interactions. Adv. Drug Deliv. Rev. 32:119–138.
Pardridge, W. M. 1999. Vector-mediated drug delivery to the brain. Adv. Drug Deliv. Rev. 36:299–321.
Pardridge, W. M. 2002. Drug and gene delivery to the brain: the vascular route. Neuron 36:555–558.
Pardridge, W. M. 2003. Blood-brain-barrier drug targeting: the future of brain drug development. Mol. Interv. 3:90–105.
Pardridge W. M. 2005. Molecular biology of the blood-brain barrier. Mol. Biotechnol. 30:57–70.
Philippova, O. E., Hourdet, D., Audebert, R., and Khokhlov, A. R. 1997. pH-Responsive gels of hydrophobically modified poly(acrylic acid). Macromolecules 30:8278–8285.
Qian, Z. M., Li, H., Sun, H., and Ho, K. 2002. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54:561–587.
Qiu, L. Y. and Bae, Y. H. 2006. Polymer architecture and drug delivery. Pharm. Res. 23:1–30.
Reddy, J. A., Allagadda, V. M., and Leamon, C. P. 2005. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr. Pharm. Biotechnol. 6:131–150.
Ringsdorf, H. 1975. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 51:135–153.
Roldo, M., Hornof, M., Caliceti, P., and Bernkop-Schnurch, A. 2004. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur. J. Pharm. Biopharm. 57:115–121.
Rozema, D. B., Ekena, K., Lewis, D. L., Loomis, A. G., and Wolff, J. A. 2003. Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules. Bioconjug. Chem. 14:51–57.
Ruiz, F., Alvarez, G., Ramos, M., Hernandez, M., Bogonez, E., and Satrustegui, J. 2000. Cyclosporin A targets involved in protection against glutamate excitoxicity. Eur. J. Pharmacol. 404:29–39.
Saito, G., Swanson, J. A., and Lee, K. D. 2003. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55:199–215.
Schneerson, R., Kubler-Kielb, J., Liu, T. Y., Dai, Z. D., Leppla, S. H., Yergey, A., Backlund, P., Shiloach, J., Majadly, F., and Robbins, J. B. 2003. Poly(γ-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. USA 100:8945–8950.
Schrama, D., Reisfeld, R. A., and Becker, J. C. 2006. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5:147–159.
Seymour, L. W., Duncan, R., Strohalm, J., and Kopecek, J. 1987. Effect of molecular weight of N-(2-Hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 21:1341–1358.
Singh, M. 1999. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Res. 5:443–451.
Sinha, V. R. and Kumria, R. 2001. Polysaccharides in colon-specific drug delivery. Int. J. Pharm. 214:19–38.
Skarlatos, S., Yoshikawa, T., and Pardridge, W. M. 1995. Transport of [125I]-transferrin through the rat blood-brain barrier. Brain Res. 683:164–171.
Solit, D. B. and Rosen, N. 2007. Targeting HER2 in prostate cancer: where to next? J. Clin. Oncol. 3:241–243.
Sprincl, L., Exner, J., Sterba, O., and Kopecek, J., 1976. New types of synthetic infusion solutions. III. Elimination and retention of poly[N-(2-hydroxypropyl) methacrylamide] in a test organism. J. Biomed. Mater. Res. 10:953–963.
Sugahara, S., Okuno, S., Yano, T., Hamana, H., and Inoue, K. 2001. Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol. Pharm. Bull. 24:535–543.
Summerton, J. and Weller, D. 1997. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev. 7:187–195.
Takeda, A. L., Colquitt, J. L., Clegg, A. J, and Jones, J. 2007. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br. J. Ophthalmol. 91:1177–1182.
Taylor, E. M. 2002. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharmacokinet. 41:81–92.
Thorstensen, K. and Romslo, I. 1993. The transferrin receptor: its diagnostic value and its potential as therapeutic target. Scand. J. Clin. Lab. Invest. 53:113–120.
Tomlinson, R., Heller, J., Brocchini, S., and Duncan, R. 2003. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. Bioconjug. Chem. 14:1096–1106.
Torchilin, V. P. and Lukyanov, A. N. 2003. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today 8:259–266.
Turk, M. J., Reddy, J. A., Chmielewski, J. A., and Low, P. S. 2002. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim. Biophys. Acta 1559:56–68.
Wang, Y., Dias, J. A., Nimec, Z., Rotundo, R., O’Conner, B. M., Freisheim, J., and Galivan, J. 1993. The properties and function of gama-glutamyl hydrolase and poly-gamma-glutamate. Adv. Enzyme Regul. 33:207–218.
Wang, L., Kristensen, J., and Ruffner, D. E. 1998. Delivery of antisense oligonucleotides using HPMA polymer: synthesis of a thiol polymer and its conjugation to water-soluble molecules. Bioconjug. Chem. 9:749–757.
Wang, G., Ahmad, K. A., Unger, G., Slaton, J. W., and Ahmed, K. 2006. CK2 signaling in androgen-dependent and -independent prostate cancer. J. Cell Biochem. 99:382–391.
West, K. R. and Otto, S. 2005. Reversible covalent chemistry in drug delivery. Curr. Drug Discov. Technol. 2:123–160.
Yao, J. C. 2007. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 21:163–172.
Yoshida, T., Oide, N., Sakamoto, T., Yotsumoto, S., Negishi, Y., Tsuchiya, S., and Aramaki, Y. 2006. Induction of cancer cell-specific apoptosis by folate-labeled cationic liposomes. J. Control. Release 111:325–332.
Younes, M. N., Park, Y. W., Yazici, Y. D., Gu, M., Santillan, A. A., Nong, X., Kim, S., Jasser, S. A., El-Naggar, A. K., and Myers, J. N. 2006. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol. Cancer Ther. 5:2696–2705.
Zhang, Y. and Bhavnani, B. R. 2006. Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. BMC Neurosci. 7:49–71.
Zhang, Y. and Pardridge, W. M. 2005. Delivery of β-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J. Pharmacol. Exp. Ther. 313:1075–1081.
Zhang, Y., Zhang, Y. F., Bryant, J., Charles, A., Boado, R. J., and Pardridge, W. M. 2004. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10:3667–3677.
Zinner, R. G. and Herbst, R. S. 2004. Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. Clin. Lung Cancer 5(Suppl 2):S67–S74.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Ljubimova, J.Y., Black, K.L., Ljubimov, A.V., Holler, E. (2008). Biodegradable Multitargeting Nanoconjugates for Drug Delivery. In: Torchilin, V. (eds) Multifunctional Pharmaceutical Nanocarriers. Fundamental Biomedical Technologies, vol 4. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76554-9_8
Download citation
DOI: https://doi.org/10.1007/978-0-387-76554-9_8
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-76551-8
Online ISBN: 978-0-387-76554-9
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)